Chronic Constipation

11
Pipeline Programs
6
Companies
9
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
6
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 8 programs with unclassified modality

On Market (2)

Approved therapies currently available

Takeda
MOTEGRITYApproved
prucalopride
Takeda
oral2018
U
PRUCALOPRIDE SUCCINATEApproved
prucalopride
Unknown Company
oral2025

Competitive Landscape

5 companies ranked by most advanced pipeline stage

City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
Elobixibat 10mgPhase 41 trial
Active Trials
NCT05165199UnknownEst. Mar 2023
Takeda
TakedaTOKYO, Japan
1 program
1
prucalopridePhase 41 trial
Active Trials
NCT01707667Completed13Est. Nov 2013
Ironwood Pharmaceuticals
5 programs
1
4
LinaclotidePhase 3Peptide1 trial
Linaclotide 290 microgramsPhase 31 trial
Linaclotide 290 microgramsPhase 31 trial
Matching PlaceboPhase 31 trial
linaclotide acetatePhase 21 trial
Active Trials
NCT00402337CompletedEst. Feb 2008
NCT00765999CompletedEst. Jan 2012
NCT01642914CompletedEst. Aug 2013
+2 more trials
E
EisaiChina - Liaoning
1 program
1
AJG555Phase 31 trial
Active Trials
NCT02961556Completed39Est. Aug 2017
Ipsen
IpsenChina - Tianjin
1 program
1
PEG 4000Phase 31 trial
Active Trials
NCT00255372Completed88Est. May 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
City TherapeuticsElobixibat 10mg
Takedaprucalopride
EisaiAJG555
Ironwood PharmaceuticalsLinaclotide 290 micrograms
Ironwood PharmaceuticalsLinaclotide
Ironwood PharmaceuticalsLinaclotide 290 micrograms
Ironwood PharmaceuticalsMatching Placebo
IpsenPEG 4000
Ironwood Pharmaceuticalslinaclotide acetate

Clinical Trials (9)

Total enrollment: 140 patients across 9 trials

NCT05165199City TherapeuticsElobixibat 10mg

Elobixibat for Chronic Constipation Without Defecation Desire

Start: Mar 2022Est. completion: Mar 2023
Phase 4Unknown
NCT01707667Takedaprucalopride

Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity

Start: Feb 2013Est. completion: Nov 201313 patients
Phase 4Completed
NCT02961556EisaiAJG555

General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation

Start: Nov 2016Est. completion: Aug 201739 patients
Phase 3Completed
NCT01642914Ironwood PharmaceuticalsLinaclotide 290 micrograms

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

Start: Aug 2012Est. completion: Aug 2013
Phase 3Completed
NCT00765999Ironwood PharmaceuticalsLinaclotide

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Start: Oct 2008Est. completion: Jan 2012
Phase 3Completed
NCT00765882Ironwood PharmaceuticalsLinaclotide 290 micrograms

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Start: Sep 2008Est. completion: Aug 2009
Phase 3Completed
NCT00730015Ironwood PharmaceuticalsMatching Placebo

Trial of Linaclotide in Patients With Chronic Constipation

Start: Aug 2008Est. completion: Oct 2009
Phase 3Completed
NCT00255372IpsenPEG 4000

To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.

Start: Apr 2005Est. completion: May 200888 patients
Phase 3Completed
NCT00402337Ironwood Pharmaceuticalslinaclotide acetate

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

Start: Nov 2006Est. completion: Feb 2008
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space